Volume 5 Supplement 1
Kaposi’s sarcoma-associated herpesvirus (KSHV) serum DNA not associated with subsequent non-Hodgkin’s lymphoma (NHL) risk
© D'Souza et al; licensee BioMed Central Ltd. 2010
Published: 11 October 2010
Non-Hodgkin’s lymphoma (NHL) is a diverse group of cancers, elevated in HIV-infected individuals. Kaposi’s sarcoma-associated herpes virus (KSHV) is found in a subset of NHL tumors, and could therefore be a cause of NHL. However, antibody testing for KSHV has limited sensitivity and specificity and studies have not associated KSHV antibodies with NHL odds. KSHV DNA in serum is a more specific marker of KSHV infection.
We performed a nested case-control study in the Multicenter AIDS Cohort Study, including 155 incident NHL cases occurring between 1984 and 2006 and non-cancer controls matched by study entry and time at risk. KSHV DNA was tested in pre-diagnostic serum from within 5 years before diagnosis using real-time quantitative PCR. Risk factors for NHL were evaluated with conditional logistic regression models.
Comparison of KSHV DNA and KSHV seropositivity among 155 HIV-positive incident NHL cases compared to 155 HIV-positive matched controls.
OR (95% CI)
KSHV serum DNA: ≥1 copy detected
Among subset with serum within 1 year before diagnosis
Among subset without Kaposi sarcoma diagnosis
Among those developing NHL after AIDS
KSHV antibodies: seroprevalent
We found no significant independent association between KSHV DNA in pre-diagnostic serum with overall odds of NHL in this nested case control study. This research suggests that, similar to KSHV antibodies, KSHV serum DNA does not have predictive value for NHL risk and KSHV is not a primary cause of NHL in HIV-positive men who have sex with men.
This article has been published as part of Infectious Agents and Cancer Volume 5 Supplement 1, 2010: Proceedings of the 12th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI).The full contents of the supplement are available online at http://www.biomedcentral.com/1750-9378/5?issue=S1.
This article is published under license to BioMed Central Ltd.